NDA 202895 · Janssen Prods
Prezista
Darunavir · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Mar 31, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Dec 16, 2011
Approved uses
6
Original approval plus efficacy supplements
Registered trials
247
74 Phase 3, 6 recruiting
FAERS reports
15,121
13,236 serious, 1,506 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 29, 2025.
PREZISTA, co-administered with ritonavir (PREZISTA/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. ( 1 )
Mechanism: Darunavir is an HIV-1 antiviral drug [see Microbiology (12.4) ] . Mechanism of Action Darunavir is an inhibitor of the HIV-1 protease. It selectively inhibits the cleavage of HIV-1 encoded Gag-Pol polyproteins in infected cells, thereby preventing the formation of mature virus particles.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 21, 2019 Supplement 24 · Efficacy LabelLetter
- Jun 17, 2016 Supplement 17 · Efficacy · priority review LabelLetter
- Apr 24, 2013 Supplement 4 · Efficacy LabelLetter
- Feb 1, 2013 Supplement 5 · Efficacy · priority review LabelLetter
- Feb 1, 2013 Supplement 6 · Efficacy · priority review LetterLabel
- Dec 16, 2011 Original approval · Type 3 - New Dosage Form · priority review LabelPediatric Written RequestPediatric Amendment 1
1 products under this application
- PREZISTA · DARUNAVIR 100MG/ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Darunavir" as an intervention, any sponsor and status, largest first.
- Comparative Study of Three NNRTI-Sparing HAART RegimensPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00811954 · 1,814 participants · Start May 2009 · Primary completion Jun 2013
Drug: Emtricitabine/tenofovir disoproxil fumarate; Raltegravir and 3 more · For: HIV Infection
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 57 sites in all
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
NCT02269917 · 1,149 participants · Start Mar 2015 · Primary completion Feb 2017
Drug: D/C/F/TAF; Boosted Protease Inhibitor (bPI) and 1 more · For: Human Immunodeficiency Virus Type 1
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 79 sites in all
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyPivotal-lookingStatus unknown
Kirby InstituteGovernment (non-federal)
NCT03017872 · 831 participants · Start Nov 23, 2017 · Primary completion Nov 11, 2022
Drug: NRTIs; Dolutegravir and 2 more · For: HIV Infections
Sites: Isidro Casanova, Argentina; Buenos Aires, Argentina; Rosario, Argentina · 28 sites in all
- Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1Pivotal-lookingTerminated
ViiV HealthcareGSK (GSK)
NCT01345630 · 813 participants · Start Sep 2011 · Primary completion Aug 2013
Drug: Maraviroc; Emtricitabine/tenofovir and 3 more · For: HIV-1
Sites: Birmingham, Alabama; Hobson City, Alabama; Hayward, California · 177 sites in all
- Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve SubjectsPivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01066962 · 800 participants · Start Aug 2010 · Primary completion Oct 2013
Drug: darunavir/ritonavir QD + raltegravir BID; darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination) · For: HIV Infections
Sites: Vienna, Austria; Antwerp, Belgium; Brussels, Belgium · 77 sites in all
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaPivotal-lookingNot yet recruiting
University College, LondonAcademic, hospital or other
NCT07792096 · 800 participants (planned) · Start Nov 2026 · Primary completion Jun 2029
Drug: Dolutegravir (DTG); Abacavir (ABC) and 5 more · For: HIV Infection
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02275780 · 769 participants · Start Dec 1, 2014 · Primary completion Sep 29, 2016
Drug: Doravirine; Darunavir and 2 more · For: HIV-1
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy1,163
- drug interaction992
- pain891
- emotional distress813
- anxiety812
- anhedonia705
- chronic kidney disease572
- exposure during pregnancy571
- maternal exposure during pregnancy538
- death500
- diarrhoea500
- renal failure498
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 21 |
| 2007 | 211 |
| 2008 | 395 |
| 2009 | 524 |
| 2010 | 535 |
| 2011 | 427 |
| 2012 | 646 |
| 2013 | 816 |
| 2014 | 878 |
| 2015 | 1,271 |
| 2016 | 1,295 |
| 2017 | 982 |
| 2018 | 1,200 |
| 2019 | 1,174 |
| 2020 | 1,304 |
| 2021 | 926 |
| 2022 | 853 |
| 2023 | 595 |
| 2024 | 522 |
| 2025 | 324 |
| 2026 | 222 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prezista (Darunavir)
2024 spending
$24.7M
Beneficiaries
2,970
12,315 claims
Per beneficiary
$8,329
$53.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $229,126,832 |
| 2021 | $202,037,571 |
| 2022 | $187,152,790 |
| 2023 | $133,001,203 |
| 2024 | $24,737,763 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Symtuza® in clinical practice.
Luis Casado J, Fontecha M, Monsalvo M, et al. · Enferm Infecc Microbiol Clin (Engl Ed) 2018 · Clinical Trial, Phase III
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.
Mandelbrot L, Tubiana R, Frange P, et al. · J Antimicrob Chemother 2023 · Clinical Trial, Phase II, Multicenter Study
- Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.
Smith KY, Garcia F, Kumar P, et al. · J Natl Med Assoc 2012 · Clinical Trial, Phase III, Meta-Analysis
- Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.
Tsirizani L, Mohsenian Naghani S, Waalewijn H, et al. · J Antimicrob Chemother 2024 · Research Support, Non-U.S. Gov't, Randomized Controlled Trial
- Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, et al. · Lancet HIV 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.